Yemi Onakunle Ph.D, MBA is co-founder and CEO of Mabswitch Inc, and has over 25 year’s experience working in the biopharmaceutical industry having served in research and executive business development roles at leading biopharmaceutical companies globally including Lonza, Diosynth and Merck. Most recently he was Chief Business Officer at Selexis where he orchestrated the execution of over 70 research collaboration and licensing deals with aggregate value over $1bn and was instrumental to the company’s acquisition in 2017. Yemi received his Ph.D in microbiology from the University of Kent at Canterbury and his MBA from the Imperial College Management School, both in the UK.